Serum Expression of Seven MicroRNAs in Chronic Lymphocytic Leukemia Patients

References

• Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl). 2004;13(3):279–287. doi:10.1111/ecc.2004.13.issue-315196232
   PubMed Web of Science ®Google Scholar
• Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes: presented in part at the 42nd annual meeting of the American Society of Hematology, December 1- 5, 2000, San Francisco, CA. Blood. 2002;99(11):4087–4093. doi:10.1182/blood.V99.11.408712010811
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37. doi:10.1038/nrc276419956173
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia: presented in part at the 40th Annual Meeting of The American Society of Hematology, held in Miami Beach, FL, December 4- 8, 1998. Blood. 1999;94(6):1840–1847. doi:10.1182/blood.V94.6.184010477712
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101(12):4944–4951. doi:10.1182/blood-2002-10-330612595313
   PubMed Web of Science ®Google Scholar
• Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990;323(11):720–724. doi:10.1056/NEJM1990091332311052201915
   PubMed Web of Science ®Google Scholar
• Abbott BL. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist. 2006;11(1):21–30. doi:10.1634/theoncologist.11-1-2116401710
   PubMed Web of Science ®Google Scholar
• Kröber A, Seiler T, Benner A, et al. V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100(4):1410–1416. doi:10.1182/blood.V100.4.1410.h81602001410_1410_141612149225
   PubMed Web of Science ®Google Scholar
• Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107(2):742–751. doi:10.1182/blood-2005-05-209316179374
   PubMed Web of Science ®Google Scholar
• Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup Phase III trial E2997. J Clin Oncol. 2007;25(7):799–804. doi:10.1200/JCO.2006.08.308917283363
   PubMed Web of Science ®Google Scholar
• Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemo immunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006;24(3):437–443. doi:10.1200/JCO.2005.03.102116344317
   PubMed Web of Science ®Google Scholar
• Alsagaby SA, Brennan P, Pepper C. Key molecular drivers of chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2016;16(11):593–606. doi:10.1016/j.clml.2016.08.00827601002
   PubMed Web of Science ®Google Scholar
• Billard C. Apoptosis inducers in chronic lymphocytic leukemia. Oncotarget. 2014;5(2):309. doi:10.18632/oncotarget.v5i224525395
   PubMedGoogle Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi:10.1016/S0092-8674(04)00045-514744438
   PubMed Web of Science ®Google Scholar
• McManus MT. MicroRNAs and cancer. Semin Cancer Biol. 2003;13(4):253–258. doi:10.1016/S1044-579X(03)00038-514563119
   PubMed Web of Science ®Google Scholar
• Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–179. doi:10.1146/annurev.med.59.053006.10470719630570
   PubMed Web of Science ®Google Scholar
• Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101(9):2999–3004. doi:10.1073/pnas.030732310114973191
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233. doi:10.1016/j.cell.2009.01.00219167326
   PubMed Web of Science ®Google Scholar
• Baumann T, Delgado J, Santacruz R, et al. CD 49d (ITGA 4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status. Br J Haematol. 2016;172(1):48–55. doi:10.1111/bjh.1378826559905
   PubMed Web of Science ®Google Scholar
• Alsagaby SA, Alhumaydhi FA. Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia. Saudi Med J. 2019;40(4):317–327. doi:10.15537/smj.2019.4.2359830957124
   PubMed Web of Science ®Google Scholar
• Lu Y, Thomson JM, Wong HY, Hammond SM, Hogan BL. Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol. 2007;310(2):442–453. doi:10.1016/j.ydbio.2007.08.00717765889
   PubMed Web of Science ®Google Scholar
• He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447(7148):1130. doi:10.1038/nature0593917554337
   PubMed Web of Science ®Google Scholar
• Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469(7330):336. doi:10.1038/nature0978321248840
   PubMed Web of Science ®Google Scholar
• Nakasa T, Miyaki S, Okubo A, et al. Expression of microRNA‐146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 2008;58(5):1284–1292. doi:10.1002/art.2342918438844
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Croce CM, Garzon R. Micro-RNA expression and function in lymphomas. Adv Hematol. 2011;2011:1–12. doi:10.1155/2011/347137
   Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99(24):15524–15529. doi:10.1073/pnas.24260679912434020
   PubMed Web of Science ®Google Scholar
• Visone R, Veronese A, Balatti V, Croce CM. MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget. 2012;3(2):195.22350310
   PubMedGoogle Scholar
• Balatti V, Pekarky Y, Croce CM. Role of microRNA in chronic lymphocytic leukemia onset and progression. J Hematol Oncol. 2015;8(1):12. doi:10.1186/s13045-015-0112-x25886051
   PubMed Web of Science ®Google Scholar
• Feng Y, Liu J, Kang Y, et al. miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. J Exp Clin Cancer Res. 2014;33(1):67. doi:10.1186/s13046-014-0067-825107371
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Uotani K, Yoshida A, et al. Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma. Oncotarget. 2017;8(20):33375. doi:10.18632/oncotarget.v8i2028380419
   PubMedGoogle Scholar
• Li M, Song Q, Li H, Lou Y, Wang L, Ray RB. Circulating miR-25-3p and miR-451a may be potential biomarkers for the diagnosis of papillary thyroid carcinoma. PLoS One. 2015;10(7):e0132403. doi:10.1371/journal.pone.013240326168287
   PubMed Web of Science ®Google Scholar
• Jin Y, Yu D, Tolleson WH, et al. MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes. Biochem Pharmacol. 2016;113:88–96. doi:10.1016/j.bcp.2016.06.00727311985
   PubMed Web of Science ®Google Scholar
• Xiang J, Hang JB, Che JM, Li HC. miR-25 is up-regulated in non-small cell lung cancer and promotes cell proliferation and motility by targeting FBXW7. Int J Clin Exp Pathol. 2015;8(8):9147.26464659
   PubMed Web of Science ®Google Scholar
• Filip AA, Grenda A, Popek S, et al. Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL—another piece in the puzzle. Ann Hematol. 2017;96(1):33–50. doi:10.1007/s00277-016-2840-627730344
   PubMed Web of Science ®Google Scholar
• He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828. doi:10.1038/nature0355215944707
   PubMed Web of Science ®Google Scholar
• Olive V, Bennett MJ, Walker JC, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009;23(24):2839–2849. doi:10.1101/gad.186140920008935
   PubMed Web of Science ®Google Scholar
• Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA. 2008;105(40):15535–15540. doi:10.1073/pnas.080826610518832181
   PubMed Web of Science ®Google Scholar
• Chen L, Li C, Zhang R, et al. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett. 2011;309(1):62–70. doi:10.1016/j.canlet.2011.05.01721664042
   PubMed Web of Science ®Google Scholar
• Li H, Wu Q, Li T, et al. The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review. Oncotarget. 2017;8(28):45060.28178677
   PubMedGoogle Scholar
• Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005;65(21):9628–9632. doi:10.1158/0008-5472.CAN-05-235216266980
   PubMed Web of Science ®Google Scholar
• Zhang R, Xu J, Zhao J, Bai J. Mir-30d suppresses cell proliferation of colon cancer cells by inhibiting cell autophagy and promoting cell apoptosis. Tumour Biol. 2017;39(6):1010428317703984. doi:10.1177/101042831770398428651493
   PubMedGoogle Scholar
• Xiang KM, Li XR. MiR-133b acts as a tumor suppressor and negatively regulates TBPL1 in colorectal cancer cells. Asian Pac J Cancer Prev. 2014;15(8):3767–3772. doi:10.7314/APJCP.2014.15.8.376724870791
   PubMedGoogle Scholar
• Li X, Sanda T, Look AT, Novina CD, von Boehmer H. Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. J Exp Med. 2011;208(4):663–675. doi:10.1084/jem.2010238421464222
   PubMed Web of Science ®Google Scholar